Navigation Links
Drug therapy to bolster immune system cells found effective toward childhood cancer
Date:5/15/2008

CINCINNATI, OH - Researchers from The University of Texas M. D. Anderson Cancer Center have found a possible approach to therapy that may make cancer cells more sensitive to attack by immune system cells while making the immune system cells more powerful.

The combination has the potential to treat different types of childhood cancer, including osteosarcoma, leukemia and neuroblastoma, while possibly sparing young patients from more difficult therapies such as stem cell transplant or more toxic chemotherapy.

Dean Lee, M.D., Ph.D., assistant professor of pediatrics from the Children's Cancer Hospital at M. D. Anderson, has found that combining the epigenetic drug MS-275 with natural killer (NK) cells makes osteosarcoma cells more sensitive to NK cells while making the NK cells more lethal to the tumor, as presented at the American Society of Pediatric Hematology/Oncology annual meeting on May 15.

"Traditional chemotherapy drugs kill any fast-growing cells like cancer, but they also killed healthy fast-growing cells like hair, bone marrow and mucous membranes, making the drugs very toxic," says Lee, senior investigator on the study. "There's a new class of drugs that takes cells that aren't properly regulated and makes them behave. In our study, we found that these drugs make tumor cells more recognizable and vulnerable to natural killer cells."

Osteosarcoma is a rare pediatric cancer, but the most common bone cancer found in children. According to the American Cancer Society, it affects approximately 400 children, adolescents and young adults under the age of 20 in the United States each year, and nearly a third of those relapse. Relapsed and metastatic osteosarcomas are rarely sensitive to treatment with chemotherapy or radiation, but several studies have suggested these tumors may be immunologically responsive.

Lee's study of human tissue cultures shows the synergistic effect of combining NK cells with histone deacetylase (HDAC) inhibitors such as MS-275 to fight childhood cancer, which Lee hopes will lead to a clinical trial for patients. When added to a human tissue culture, MS-275 heightened the amount of the NKG2D receptor on the NK cell's surface to pick up signals from stressed cells, such as tumor cells. In addition, the MS-275 simultaneously caused the stress signals of the tumor cells to increase, making it easier for NK cells to detect them and kill them.

Trials are currently open using HDAC and proteasome inhibitors as well as NK cells to treat patients, but not as a combination therapy.

"By applying what we've found from our study, we hope to improve our treatment for many cancers, but not by giving more NK cells or by giving more toxic chemotherapy," says Lee. "Instead, we want to marry the two therapies to improve each other and provide a more effective, less toxic treatment for our patients."

Lee's study found similar responses from acute myelogenous leukemia (AML) and neuroblastoma, but using different inhibitors. For neuroblastoma and AML, the proteasome inhibitors Bortezomib and NPI-0052 were found to have the greatest effect on sensitizing tumor cells to NK cells. Additional research is being conducted on acute lymphocytic leukemia, the most common cancer in children, and medulloblastoma, the most common brain cancer in children.


'/>"/>

Contact: Sara Farris
sfarris@mdanderson.org
281-467-1337
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
2. Blacks not receiving chemotherapy for rectal cancer, despite seeing cancer specialists
3. Drug therapy for PKU reverses heart damage
4. Therapy Yields Promise for Fatal Neurological Condition
5. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
6. NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease
7. Psychology.com Seeing Growing Acceptance of Online Therapy
8. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
9. Paro, the Worlds Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2
10. Arsenic-based therapy shown to help eradicate leukemia-initiating cells
11. FDA Says, Wait To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug therapy to bolster immune system cells found effective toward childhood cancer
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: